SCHEDULE: Dawei Luo Discloses 8.52% Passive Stake in Vivos Therapeutics Inc.

Dawei Luo has filed a Schedule 13G, revealing a passive beneficial ownership of 8.52% of Vivos Therapeutics Inc.'s common stock, totaling 572,016 shares.

Summary

• Dawei Luo, a citizen of the People's Republic of China, has reported beneficial ownership of 572,016 shares of Vivos Therapeutics Inc. common stock.
• This ownership represents 8.52% of the company's outstanding common stock.
• The percentage is calculated based on 5,889,520 shares outstanding as of May 15, 2025, plus an additional 828,000 shares issued on June 9, 2025, in a private financing.
• The shares are held with sole voting and dispositive power by Dawei Luo, with 445,205 shares directly owned and 126,811 shares owned through Space Star Holding Ltd, a wholly-owned entity.
• The acquisition of these securities is for passive investment purposes and not for changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The filing indicates a new significant passive investment, which is generally a neutral to slightly positive signal as it shows an investor's confidence, albeit without intent to influence control.

Positives

• A significant individual investor, Dawei Luo, has taken an 8.52% passive stake in Vivos Therapeutics Inc., potentially signaling confidence in the company's long-term prospects.
• The investment is explicitly stated as passive, indicating no immediate intent to influence or change control of the company.

Negatives

• No direct negatives are indicated in this Schedule 13G filing.

Risks

• The filing itself does not detail specific risks related to Vivos Therapeutics Inc.'s operations or financial health, as it is a beneficial ownership disclosure.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing indicates a new significant passive investment in Vivos Therapeutics Inc., a company operating in the healthcare or medical device sector (implied by 'Therapeutics'). Such investments can reflect investor confidence in the specific company or the broader industry's growth potential, though this filing does not provide broader industry analysis.

Comparison to Industry Standards

• This Schedule 13G filing is a standard disclosure for a beneficial ownership stake exceeding 5%.
• It does not provide financial or operational results that can be directly compared to industry benchmarks or specific comparable companies or projects.
• The filing's content is limited to the details of the ownership stake itself.

Stakeholder Impact

• Shareholders: The disclosure of a new significant passive investor may be viewed positively, potentially increasing market confidence.
• Management: The passive nature of the investment suggests no immediate pressure or intent to influence corporate strategy or governance from this investor.

Next Steps

• The document does not outline any specific future actions, events, or milestones for Vivos Therapeutics Inc. or the reporting person beyond the passive investment.

Key Dates

Recommendation

Keywords

Vivos Therapeutics Inc., VIVO, Dawei Luo, Schedule 13G, Beneficial Ownership, Common Stock, Passive Investment, SEC Filing, Shareholder, Equity Stake